← Eichor
Study identifier: NCT06803706 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community

Condition: Substance Use Disorder (SUD) · Alcohol Use Disorder (AUD) · Nicotine Addiction  ·  Sponsor: Sigmund Freud PrivatUniversitat

PhaseNA
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

Theoretical Framework: Cigarette smoking is the leading preventable cause of death worldwide, with nicotine dependence notably common among individuals with Substance Use Disorders (SUD). Smoking exacerbates both physical and mental health issues, further complicating the treatment of SUD. Current therapeutic approaches for SUD often prove inadequate, indicating a need for new strategies. Recent advancements in metabolomics and gut microbiome research have provided valuable insights into the biological mechanisms underlying addiction. Objectives: This study aims to investigate the therapeutic potential of smoking cessation for individuals with SUD, using a six-week intervention within a therapeutic community. The research specifically explores the psychobehavioral, metabolic, and gut microbiome domains. It is hypothesized that smoking cessation will improve emotional regulation, self-efficacy, and reduce substance craving, mediated by changes in metabolic and microbiome profiles linked to brain reward systems. Methods: A randomized controlled trial (N=150) will be conducted, examining outcomes such as clinical relapse rates, microbial and metabolic markers, particularly in choline and folate metabolism. Participants with SUD (n=100) will undergo a six-week smoking cessation intervention, with pre- and post-assessments, compared to a control group receiving treatment as usual. Metabolomic and microbiome analyses will be conducted using blood and stool samples, alongside psyc…

This description comes directly from the study's public registry record.

Talk to the study team

Human F Unterrainer, Professor  ·  +43-699-181-95-990  ·  human.unterrainer@sfu.ac.at

Johannes Peter, MSc  ·  +43-6606941409  ·  johannes.peter@sfu.ac.at

Always discuss trial participation with your own doctor first.

Locations (3)

Grüner Kreis Organization Johnsdorf FacilityFehring, AustriaRecruiting
Medical University GrazGraz, AustriaRecruiting
Sigmund Freud Private University ViennaVienna, AustriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06803706